Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial

Shaji Kumar, Philippe Moreau, Anjla Sood et al.|The Lancet Oncology|2020

Cited by 401